StocksMedium•16 November 2026•
1 min read
Iambic Expands AI Partnerships with Bayer and AbbVie, Reports $24M YTD Revenue
Key Facts
1Iambic announced new AI drug discovery collaborations with Bayer and AbbVie, bringing its total partnerships to eight.
2The company generated $24 million in collaboration revenue YTD through Q3 2026, maintaining a cash position of $252 million.
3Iambic triggered a $1.0 million milestone payment from Takeda just nine months after starting their collaboration.
Iambic announced new AI drug discovery collaborations with Bayer and AbbVie, bringing its total number of partnerships to eight. According to a GlobeNewswire report, the company generated $24 million in collaboration revenue year-to-date through the third quarter of 2026, while maintaining a strong cash position of $252 million.
The company also triggered a $1.0 million milestone payment from Takeda following technical progress in their joint program just nine months after initiation. Regarding partner equity performance, ABBV closed at $295.03, BAYRY at $15.66, and TAK at $21.43 on November 13, 2026.